Sue D. Pedersen - Concepedia

Author

Sue D. Pedersen

LMC Diabetes & Endocrinology (Canada)ORCID

Also Known As

James Conway, S D Pedersen, S. D. Pedersen, S. Pedersen, S.D. Pedersen, SUE D. PEDERSEN, SUE PEDERSEN, Sigrid Kammer Pedersen, Stig Schack Pedersen, Sue D Pedersen

Publications

11K

Citations

H-Index

Concepts

All Affiliations

LMC Diabetes & Endocrinology (Canada)Novo Nordisk (Denmark)University of Copenhagen University of Calgary The University of Texas Southwestern Medical Center

About

Sue D. Pedersen is an author at LMC Diabetes & Endocrinology (Canada) specializing in medicine, diabetes, and obesity.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	6.4K
2	Health Sciences	5	5	1.3K
3	Public Health	2	2	2.8K
4	Social Sciences	1	1	33
5	Clinical Nutrition	1	1	79

Sue D. Pedersen

Publications

10.5K

Citations

H-Index

Page 1

	Year	Citations
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, The Lancet Metabolic SyndromeDiabetes ManagementCardiovascular DiseaseHealth PolicyCardiovascular Outcomes	2019	2.8K
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark, New England Journal of Medicine	2019	1.8K
Obesity in adults: a clinical practice guideline Sean Wharton, David C.W. Lau, Michael Vallis, Canadian Medical Association Journal	2020	1.3K
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Melanie J. Davies, Louise Færch, Ole Kleist Jeppesen, The Lancet ObesityDiabetes ManagementMedicineDiabetesClinical Trials	2021	1.2K
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial Patrick M. O’Neil, Andreas L. Birkenfeld, Barbara McGowan, The Lancet ObesityNon-pharmacological InterventionWeight LossPharmacologyClinical Trials	2018	751
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais, The Lancet Metabolic SyndromeDiabetes ManagementUrologyChronic Kidney DiseaseDiabetes	2019	600
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial Juan P. Frías, Srikanth Deenadayalan, Lars Erichsen, The Lancet Diabetes ManagementDiabetesPharmacologyClinical TrialsType 2	2023	264
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial David C.W. Lau, Lars Erichsen, Ann Marie Ocampo Francisco, The Lancet ObesityMetabolic SyndromeDose-finding Phase 2Non-pharmacological InterventionLifestyle Modification	2021	211
Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice Sean Wharton, Melanie J. Davies, Dror Dicker, Postgraduate Medicine Bariatric SurgeryGastrointestinal PharmacologyGastroenterologyGastrointestinal Peptide HormoneObesity	2021	174
Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial W. Timothy Garvey, Andreas L. Birkenfeld, Dror Dicker, Diabetes Care	2020	170

Page 1